Product Added to Cart!
$46.00

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Available on backorder. No lead time available. Please request a quote.
Sku CI35194_1_G
Chem Impex
Get Bulk Quote

Product Information

Product Name
Fmoc-L-cysteic acid
Brand Name
Chem Impex
Product Number
35194
CAS
751470-47-0
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
46737376
IUPAC Name
(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-sulfopropanoic acid
InChI Key
BUTKUPGRCQCTTA-INIZCTEOSA-N
SMILES
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NC@@H(CS(=O)(=O)O)C(=O)O

Description

Fmoc-L-cysteic acid is widely utilized in research focused on:

Peptide Synthesis: This compound serves as a protecting group in the synthesis of peptides, allowing for the selective modification of amino acids without interfering with other functional groups.

Bioconjugation: It is used in bioconjugation processes, enabling the attachment of biomolecules to surfaces or other molecules, which is crucial in drug delivery systems and diagnostics.

Protein Engineering: Researchers leverage its properties to introduce sulfonic acid groups into proteins, enhancing their solubility and stability, which is beneficial in therapeutic applications.

Analytical Chemistry: Fmoc-L-cysteic acid is employed in various analytical techniques, including chromatography, to improve the separation and identification of complex mixtures.

Drug Development: Its unique chemical structure aids in the design of novel pharmaceuticals, particularly in targeting specific biological pathways, making it valuable in the pharmaceutical industry.

References Data Source From Pubchem

Structure–activity relationship of 18F-labeled PD-L1-targeting small molecule ligands: impact of radiolabeling strategy on affinity and in vivo performance

Publication Name: EJNMMI Radiopharmacy and Chemistry
Publication Date: 2025-07-01
DOI: 10.1186/s41181-025-00359-2

Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands

Publication Name: EJNMMI Radiopharmacy and Chemistry
Publication Date: 2024-02-19
DOI: 10.1186/s41181-024-00243-5